Stockscreener 앱 받기
1.21
3.42%
0.04
Windtree Therapeutics Inc 주식(WINT)의 최신 뉴스
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN
Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria
Windtree Therapeutics announces board member resignation - Investing.com Australia
Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus
Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks
WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView
Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks
Windtree Therapeutics sees cash runway through April - TipRanks
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView
Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus
Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World
Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia
Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World
Windtree Therapeutics Delays Annual Report Filing - TipRanks
WINT stock touches 52-week low at $1.32 amid steep annual decline - Investing.com
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cos - GuruFocus
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - Marketscreener.com
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Windtree Therapeutics Inc. (WINT) Soars 14.63% on Nasdaq Compliance - AInvest
Massive 60% Cost Cut: How PHEXXI's New Deal Transforms Global Contraceptive Access - Stock Titan
Windtree Therapeutics IncOn March 20, Entered License And Supply Agreement With Evofem BiosciencesSEC Filing - MarketScreener
Windtree Therapeutics regains compliance with Nasdaq listing rules - TipRanks
Windtree Therapeutics Regains Compliance With Nasdaq Listing Rules For Continued Listing - Nasdaq
Windtree Therapeutics Regains Nasdaq Compliance Over Minimum Share Price Rule - MarketScreener
Windtree Therapeutics regains Nasdaq compliance - Investing.com India
Evofem Reports Fourth Consecutive Year of Net Sales Growth - Quantisnow
Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% - Stock Titan
Windtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - The Manila Times
Windtree Therapeutics Dodges Delisting: How The Biotech Company Saved Its Nasdaq Status - Stock Titan
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Biotech Stocks To Consider – March 20th - Defense World
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI® - MSN
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Windtree shares rise as it announces agreement to become sourcing partner for Evofem - MSN
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
Windtree Therapeutics (WINT) Climb Amid New Licensing Deal - Stocks Telegraph
Another Day, Another Biotech Ripping Before The Bell - The Globe and Mail
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga
What's Going On With Windtree Therapeutics Shares Thursday? - Benzinga
Windtree to become sourcing partner for Evofem Biosciences - TipRanks
Windtree Signs Deal to Become Sourcing Partner for Evofem's Contraceptive Vaginal Gel; Shares Rise - Marketscreener.com
Windtree partners with Evofem for contraceptive gel supply - Investing.com
Windtree's Game-Changing Deal: Manufacturing Rights to $19M FDA-Approved Contraceptive - Stock Titan
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Expands By 44.9% - Defense World
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
0.24%
36.06%
자본화:
|
볼륨(24시간):